SBIR/STTR Research Award
Cell Regulatory Sialoprotein
Award amount
$50,000Program and phase
SBIR · Phase IAward year
1993Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- Not reported
- Recipient company
- Synchrocell, Inc./dovetail
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
CeReS (Cell Regulatory Sialoprotein) is a molecule demonstrated to 1. Inhibit primary, continuous and transformed cell lines, 2. affect cells from species as diverse as insects and humans, 3. cause one cell line to terminally differentiate, 4. reversibly inhibit other lines (90%-98% of the cells recover), 5. Specifically arrest cells near the Gl/S interface, 6. synchronously release cells to enter S phase and then mitosis (synchronization remains through at least one additional cell cycle). CeReS is distinct from all known drugs and cell surface components functionally and according to the limited peptide sequence and preliminary DNA sequence data available. The aims are to determine the feasibility of using CeReS to improve and increase efficiency of cell culture, to provide new models for differentiation, and to test a wide variety of cancer cell lines for sensitivity or resistance to CeReS. Preliminary data indicates differential sensitivity of cells suggesting potential therapeutic uses. We believe this and related molecules will be important products for the research community. The research will significantly aid in understanding regulation and carcinogenesis and as a cell culture tool of commercial importance. Improved cancer therapies are potential applications of CeReS and of the knowledge gained with the aid of CeReS.
Technology keywords
Not reported